MoneyWorks4Me

USFDA concludes inspection at Alembic Pharmaceuticals’ Bioequivalence facility

25 Oct 2022 Evaluate

United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals’ Bioequivalence facility located at Vadodara. The inspection was conducted from October 17, 2022 to October 21, 2022. The company has successfully completed USFDA inspection without any observations.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..